Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2010
11/25/2010US20100297217 Isoprenoid compounds, their isolation and use
11/25/2010US20100297215 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
11/25/2010US20100297209 Solvent/polymer solutions as suspension vehicles
11/25/2010US20100297194 Formulation for oral administration of apoptosis promoter
11/25/2010US20100297189 Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine
11/25/2010US20100297172 Replication-defective arenavirus vectors
11/25/2010US20100297159 Thomsen-friedenreich disaccharide modified immunogen (tfd), preparation procedure, compositions comprising it, uses, and treatment methods
11/25/2010US20100297157 Vaccine therapy for choroidal neovascularization
11/25/2010US20100297156 Analogues of phosphatidylinositol mannosides
11/25/2010US20100297155 Phosphazene hydrogels with chemical corss-link, preparation method thereof and use thereof
11/25/2010US20100297153 Binding molecules for treatment and detection of cancer
11/25/2010US20100297152 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
11/25/2010US20100297150 Disease treatment via antimicrobial peptide inhibitors
11/25/2010US20100297149 Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
11/25/2010US20100297145 Apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer, screening method for the promoter, inhibitor or agent
11/25/2010US20100297142 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
11/25/2010US20100297140 Uses of antibodies
11/25/2010US20100297138 Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
11/25/2010US20100297137 Hematopoietic Lineage Cell Specific Protein (HS1) as a Marker for Lymphoid Malignancy
11/25/2010US20100297136 Gastric and Prostate Cancer Associated Antigens
11/25/2010US20100297134 Humanised antibodies with anti-tumour activity
11/25/2010US20100297124 Induced internalization of surface receptors
11/25/2010US20100297122 Formulations for taci-immunoglobulin fusion proteins
11/25/2010US20100297120 Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
11/25/2010US20100297118 Therapeutic Cancer Treatments
11/25/2010US20100297114 Antigen presenting cell targeted vaccines
11/25/2010US20100297113 Quinone derivatives, pharmaceutical compositions, and uses thereof
11/25/2010US20100297112 Combinations comprising dmxaa for the treatment of cancer
11/25/2010US20100297110 Antibody specific for human il-4 for the treatment of cancer
11/25/2010US20100297109 Methods for inhibiting fascin
11/25/2010US20100297094 Therapy or prevention of diseases with cells or cell supernatant
11/25/2010US20100297093 Modified t cell receptors and related materials and methods
11/25/2010US20100297091 Compositions and methods for treatment of melanomas
11/25/2010US20100297085 Synthetic Herpes Simplex Viruses Type-1 for Treatment of Cancers
11/25/2010US20100297078 Method for producing a hydroxyalkyl starch derivative with two linkers
11/25/2010US20100297076 Targeted interferon demonstrates potent apoptotic and anti-tumor activities
11/25/2010US20100297075 Combinational compositions and methods for treatment of cancer
11/25/2010US20100297072 Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
11/25/2010US20100297067 Methylation markers for prostate cancer and methods of use
11/25/2010US20100297066 Biodegradable peptide releasing polymers
11/25/2010US20100297064 Cytokine zalpha11 ligand antibodies
11/25/2010US20100297063 Cytokine zalpha11 ligand antibodies
11/25/2010US20100297061 Stat3 antagonists and their uses as vaccines against cancer
11/25/2010US20100297060 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
11/25/2010US20100297054 1,2,3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
11/25/2010US20100297046 Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors
11/25/2010US20100297025 Novel compositions magnetic particles covered with gem-bisphosphonate derivatives
11/25/2010US20100297024 Promoter inducible by reactive oxygen species and vector comprising the same
11/25/2010US20100297017 Method for Synthesizing and Using Pegylated Peptide-Photoactive Chromophore Conjugates and Micellular Formulations Thereof
11/25/2010US20100297015 Cancer biomarker and uses thereof
11/25/2010US20100297014 Method of detecting the risk of cancer using genetic markers
11/25/2010US20100297010 Tumor suppressor gene screening using rna interference libraries and method of treatment
11/25/2010US20100297008 Ganglioside associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
11/25/2010US20100297006 NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 191P4D12(b) USEFUL IN TREATMENT AND DETECTION OF CANCER
11/25/2010US20100297005 Nucleic acids and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer
11/25/2010US20100297004 High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
11/25/2010DE102010007381A1 Prophylaxemittel gegen Krebskrankheiten und erhöhte Hautspannungen Prophylaxis for cancer diseases and increased skin tension
11/25/2010CA2763099A1 Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
11/25/2010CA2762939A1 Self-emulsifying composition of .omega.3 fatty acid
11/25/2010CA2762679A1 Compositions and methods to prevent cancer by stabilizing p53 through non mdm2-mediated pathways
11/25/2010CA2762652A1 Novel solid materials of {[(2s,5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them
11/25/2010CA2762574A1 Combinations of immunostimulatory agents, oncolytic virus, and additional anticancer therapy
11/25/2010CA2762427A1 Nitrile derivatives and their pharmaceutical use and compositions
11/25/2010CA2762233A1 Anticancer compound and pharmaceutical composition containing the same
11/25/2010CA2762232A1 Substituted quinolines for use as vegf inhibitors
11/25/2010CA2762226A1 Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors
11/25/2010CA2762176A1 Marker differentially expressed in cancer stem cells and methods of using same
11/25/2010CA2762174A1 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
11/25/2010CA2761954A1 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
11/25/2010CA2760779A1 Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
11/25/2010CA2760766A1 Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
11/25/2010CA2760765A1 Disaccharin, difumaric acid, di-1-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamino)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin-5-yl) methyl) phenyl)acetate
11/25/2010CA2758222A1 Protease inhibitors
11/24/2010EP2253709A1 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
11/24/2010EP2253701A1 Method of extracting virus from cell culture
11/24/2010EP2253646A1 Anti-dual integrin antibody and compositions and conjugates comprising said antibody
11/24/2010EP2253643A1 Novel compositions and methods in cancer associated with altered expression of PRLR
11/24/2010EP2253642A1 Polypeptides, cDNAs encoding the same and utilization thereof
11/24/2010EP2253639A1 Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
11/24/2010EP2253633A1 Fused heterocyclic compound
11/24/2010EP2253629A1 Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
11/24/2010EP2253625A1 Pyridazinones, the preparation and the use thereof
11/24/2010EP2253621A1 A set of geldanamycin derivatives and their preparation methods
11/24/2010EP2253620A1 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
11/24/2010EP2253320A1 Combination of a pyrimidylaminobenzamide and a mTOR kinase inhibitor
11/24/2010EP2253319A1 Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.
11/24/2010EP2253314A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
11/24/2010EP2252688A1 Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
11/24/2010EP2252632A1 Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof
11/24/2010EP2252627A1 Lytic domain fusion constructs and methods of making and using same
11/24/2010EP2252618A1 PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS
11/24/2010EP2252616A1 Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
11/24/2010EP2252612A1 Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
11/24/2010EP2252608A1 Method for treating pain syndrome and other disorders
11/24/2010EP2252605A2 Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
11/24/2010EP2252597A2 Novel compounds, use and preparation thereof
11/24/2010EP2252595A1 Oxim derivatives as hsp90 inhibitors
11/24/2010EP2252589A2 6-and 7-amino isoquinoline compounds and methods for making and using the same
11/24/2010EP2252373A2 Novel fer -like protein, pharmaceutical compositions containing it and method for its use
11/24/2010EP2252323A2 Genetic regulation of host defense mechanisms by mucosal exposure to natural interferon alpha species
1 ... 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 ... 2211